{"id":3270,"date":"2026-09-17T09:00:00","date_gmt":"2026-09-17T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3270"},"modified":"2026-09-19T14:04:22","modified_gmt":"2026-09-19T18:04:22","slug":"sk-licenses-1st-104-for-parkinson-disease","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3270","title":{"rendered":"SK Licenses 1ST-104 for Parkinson Disease"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

SK Biopharmaceuticals \/ 1ST Biotherapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Exclusive Global License<\/p>\n

Modality<\/strong><\/p>\n

Oral Dual-Kinase Small Molecule<\/p>\n

Asset<\/strong><\/p>\n

1ST-104<\/p>\n

Target<\/strong><\/p>\n

Type 2 LRRK2 and c-Abl (Dual Inhibitor)<\/p>\n

Disease Area<\/strong><\/p>\n

Parkinson Disease<\/p>\n

Summary<\/h4>\n

SK Biopharmaceuticals licensed exclusive global rights to 1ST-104, a preclinical oral Type 2 LRRK2 and c-Abl dual inhibitor from 1ST Biotherapeutics. The agreement is valued at up to $314.8 million, including $1.8 million upfront, a further $1.8 million near-term milestone, and additional contingent milestones plus tiered royalties. SK also made a separate $2.2 million strategic equity investment. The deal validates the program’s differentiation thesis but commits limited cash ahead of any clinical evidence.<\/p>\n

The companies announced the transaction on September 17, 2026. 1ST-104 is designed to combine Type 2 LRRK2 binding with c-Abl inhibition and has shown preclinical blood-brain-barrier penetration and target selectivity. The companies position the Type 2 binding mode as a potential response to pulmonary findings that have challenged some Type 1 LRRK2 inhibitor programs. No candidate-selection timing, IND date, quantitative exposure data, pulmonary-safety dataset, in-vivo disease-modification result, or development-cost allocation was disclosed, and most of the headline $314.8 million figure is contingent rather than committed.<\/p>\n

Deep Analysis<\/h4>\n

The constructive read is that dual modulation may address complementary Parkinson disease biology, and that a Type 2 binding mode could differentiate 1ST-104 from earlier LRRK2 programs that ran into pulmonary tolerability issues. The more cautious read is that dual inhibition adds pharmacology, off-target, and dose-selection complexity without yet demonstrating that modulating either target changes the course of human disease. Blood-brain-barrier penetration is necessary but not sufficient: the program still has to show sustained CNS target engagement at exposures that avoid lung, immune, or kinase-related liabilities.<\/p>\n

The small upfront payment ($1.8 million) relative to the $314.8 million ceiling signals disciplined option value on SK’s part rather than strong clinical de-risking. Most of the value is backloaded into development and commercial milestones that depend on data that do not yet exist.<\/p>\n

Company and Product Background<\/h4>\n

Parkinson disease involves progressive loss of dopaminergic neurons and has both genetic and sporadic forms. LRRK2 variants are among the most important known genetic risk factors, while c-Abl has been implicated in cellular stress response and alpha-synuclein biology, providing a mechanistic rationale for dual targeting. 1ST Biotherapeutics is a Korean discovery-stage company; SK Biopharmaceuticals develops and commercializes central nervous system therapies globally.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Deal economics: $1.8 million upfront, $1.8 million near-term milestone, up to $314.8 million total with tiered royalties, plus a separate $2.2 million equity investment.<\/li>\n
  • Program stage: preclinical; no IND-enabling toxicology or human data disclosed.<\/li>\n
  • Differentiation thesis: Type 2 LRRK2 binding as a potential answer to pulmonary safety findings seen with some Type 1 LRRK2 inhibitors.<\/li>\n
  • Upgrade evidence: IND-enabling toxicology results, quantitative CNS pharmacokinetic\/pharmacodynamic data, clean lung histopathology, and biomarker-linked clinical proof of concept.<\/li>\n
  • Downgrade evidence\/falsifiers: narrow safety margins, inadequate brain exposure, or no evidence of disease-modifying biology once tested in vivo or in patients.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a strategically interesting but genuinely early licensing signal. The modest committed capital appropriately reflects the program’s distance from human validation. The central test is not the size of the milestone ceiling; it is whether Type 2 LRRK2 plus c-Abl inhibition produces a measurable CNS pharmacodynamic advantage without importing new toxicity, a question that preclinical data alone cannot answer.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal importance is moderate-to-high given the differentiated dual-target mechanism and global license structure, though direction is uncertain because the program remains preclinical with no human data. Confidence in the underlying facts is high, since deal economics and mechanism claims are primary-sourced, while confidence in interpretation is low-to-moderate given the absence of quantitative preclinical or safety data to assess the differentiation thesis.<\/p>\n","protected":false},"excerpt":{"rendered":"

    SK Biopharmaceuticals licensed exclusive global rights to 1ST-104, a preclinical oral Type 2 LRRK2 and c-Abl dual inhibitor from 1ST Biotherapeutics. The agreement is valued at up to $314.8 million, including $1.8 million upfront,…<\/p>\n","protected":false},"author":1,"featured_media":3282,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,2],"tags":[811,812,680],"class_list":["post-3270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-deals-and-financing","tag-1st-biotherapeutics","tag-parkinson-disease","tag-sk-biopharmaceuticals"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3270"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3270\/revisions"}],"predecessor-version":[{"id":3300,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3270\/revisions\/3300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3282"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}